UK government backs AI drug discovery firm with new venture fund
The UK Government's Sovereign AI Fund has invested in Isomorphic Labs, a London-based company using artificial intelligence to accelerate medicine design. The investment marks the fund's third equity stake since its launch last month.
Isomorphic Labs builds on AlphaFold, an AI model developed at DeepMind that predicted protein structures with new accuracy. The company has developed proprietary AI models for drug design across multiple therapeutic areas and drug types, aiming to cut years from traditional development timelines.
What Sovereign AI does
Sovereign AI provides financial backing, computing infrastructure, and expertise to early-stage and growth-stage AI companies in the UK. The fund positions itself as a mechanism to keep AI research, jobs, and economic benefits within Britain.
The UK has more AI startups than any other European country. Sovereign AI aims to accelerate that advantage by supporting companies positioned to lead globally.
Why this matters for government
Isomorphic Labs' expansion is expected to create jobs in London and strengthen the UK's scientific capabilities. The investment signals government intent to ensure major AI breakthroughs occur domestically rather than elsewhere.
The company's work on drug discovery has direct applications for healthcare systems. Faster medicine development could reduce time to treatment for patients with conditions currently difficult to address.
For professionals in government, this represents a practical example of how venture investment in AI can serve both economic and public health goals.
Learn more about AI for Healthcare and AI for Science & Research.
Your membership also unlocks:
